{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T17:37:20Z","timestamp":1777484240438,"version":"3.51.4"},"reference-count":31,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2022,3,26]],"date-time":"2022-03-26T00:00:00Z","timestamp":1648252800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Cancer Control"],"published-print":{"date-parts":[[2022,11]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Irinotecan-based doublet chemotherapy strategy was standard second-line backbone for patients with oxaliplatin-refractory metastatic colorectal cancer. The aim of this study was to evaluate tolerability and efficacy of raltitrexed combined with irinotecan biweekly administered as the second-line therapy for mCRC patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      The study was a prospective, single-center, non-randomized, open-label phase II clinical trial. Patients with mCRC after failure with oxaliplatin and fluoropyrimidine or its derivatives were enrolled. Irinotecan (180\u00a0mg\/m\n                      <jats:sup>2<\/jats:sup>\n                      ) and raltitrexed (2.5\u00a0mg\/m\n                      <jats:sup>2<\/jats:sup>\n                      ) were given intravenously on day 1. Cycles were repeated every 2 weeks. The primary endpoint was progression-free survival (PFS), and the secondary endpoints included overall response rate (ORR), disease control rate (DCR), overall survival (OS), and adverse events (AEs).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Between December 2012 and October 2016, 33 and 35 patients enrolled were assessed for response and safety, respectively. The ORR was 8.6%, and the DCR was 71.4%. The median PFS was 4.5 months (95% CI 3.8-5.2). The median OS was 12.0 months (95% CI 8.5-15.5). Four patients received conversion therapy to no evidence of disease (NED), and 2 patients were still alive with beyond 24 months survival. The most common grade 3\/4 AEs were anorexia (14.3%), vomiting (14.3%), nausea (11.4%), fatigue (8.6%), and leukopenia (8.6%). No one died from treatment-related events. The incidence and severity of toxicity were irrelevant to UGT1A1 status.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The combination of irinotecan with raltitrexed is an efficient, convenient, and acceptable toxic regimen for second-line treatment for mCRC patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/10732748221080332","type":"journal-article","created":{"date-parts":[[2022,3,26]],"date-time":"2022-03-26T22:29:05Z","timestamp":1648333745000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":4,"title":["Biweekly Raltitrexed Combined With Irinotecan as Second-Line Therapy for Patients With Metastatic Colorectal Cancer: A Phase II Trial"],"prefix":"10.1177","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6034-8872","authenticated-orcid":false,"given":"Ke","family":"Cheng","sequence":"first","affiliation":[{"name":"Department of Abdominal Oncology, Cancer Center of West China Hospital, Sichuan University, Chengdu, Sichuan, People\u2019s Republic of China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu-Wen","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Biotherapy, Cancer Center of West China Hospital, Sichuan University, Chengdu, Sichuan, People\u2019s Republic of China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ye","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Abdominal Oncology, Cancer Center of West China Hospital, Sichuan University, Chengdu, Sichuan, People\u2019s Republic of China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhi-Ping","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Abdominal Oncology, Cancer Center of West China Hospital, Sichuan University, Chengdu, Sichuan, People\u2019s Republic of China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meng","family":"Qiu","sequence":"additional","affiliation":[{"name":"Department of Abdominal Oncology, Cancer Center of West China Hospital, Sichuan University, Chengdu, Sichuan, People\u2019s Republic of China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ji-Yan","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Biotherapy, Cancer Center of West China Hospital, Sichuan University, Chengdu, Sichuan, People\u2019s Republic of China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2022,3,26]]},"reference":[{"key":"bibr1-10732748221080332","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21551"},{"key":"bibr2-10732748221080332","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.05.113"},{"key":"bibr3-10732748221080332","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)61087-3"},{"key":"bibr4-10732748221080332","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30140-2"},{"issue":"1","key":"bibr5-10732748221080332","first-page":"Cd006875","volume":"1","author":"Mocellin S","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"bibr6-10732748221080332","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdt028"},{"key":"bibr7-10732748221080332","doi-asserted-by":"publisher","DOI":"10.1023\/A:1011194712661"},{"issue":"2","key":"bibr8-10732748221080332","first-page":"1139","volume":"24","author":"Laudani A","year":"2004","journal-title":"Anticancer Res"},{"key":"bibr9-10732748221080332","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.20.4081"},{"key":"bibr10-10732748221080332","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdg285"},{"key":"bibr11-10732748221080332","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6601713"},{"key":"bibr12-10732748221080332","doi-asserted-by":"publisher","DOI":"10.1159\/000084821"},{"key":"bibr13-10732748221080332","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6600883"},{"key":"bibr14-10732748221080332","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(10)70181-9"},{"issue":"2","key":"bibr15-10732748221080332","first-page":"1391","volume":"25","author":"Chiara S","year":"2005","journal-title":"Anticancer Res"},{"key":"bibr16-10732748221080332","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.11.3357"},{"key":"bibr17-10732748221080332","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdm544"},{"key":"bibr18-10732748221080332","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2018.0021"},{"key":"bibr19-10732748221080332","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdw235"},{"key":"bibr20-10732748221080332","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.9.2943"},{"key":"bibr21-10732748221080332","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2018.02.002"},{"key":"bibr22-10732748221080332","doi-asserted-by":"publisher","DOI":"10.5603\/CJ.2012.0084"},{"key":"bibr23-10732748221080332","doi-asserted-by":"publisher","DOI":"10.1080\/0284186X.2016.1278459"},{"key":"bibr24-10732748221080332","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2017.1269"},{"key":"bibr25-10732748221080332","doi-asserted-by":"publisher","DOI":"10.1016\/j.clcc.2018.09.010"},{"key":"bibr26-10732748221080332","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2013.03.004"},{"key":"bibr27-10732748221080332","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.1998.160"},{"key":"bibr28-10732748221080332","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa033025"},{"key":"bibr29-10732748221080332","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.13.1193"},{"key":"bibr30-10732748221080332","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.09.6305"},{"key":"bibr31-10732748221080332","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(12)70477-1"}],"container-title":["Cancer Control"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10732748221080332","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10732748221080332","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10732748221080332","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T14:22:32Z","timestamp":1777386152000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10732748221080332"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,26]]},"references-count":31,"alternative-id":["10.1177\/10732748221080332"],"URL":"https:\/\/doi.org\/10.1177\/10732748221080332","relation":{},"ISSN":["1073-2748","1526-2359"],"issn-type":[{"value":"1073-2748","type":"print"},{"value":"1526-2359","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,26]]},"article-number":"10732748221080332"}}